In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation
Related Experiment Video
Updated: Aug 11, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
B Ahmed1, W Landuyt, A W Griffioen
1Laboratory Experimental Radiobiology/LEO, Catholic University Leuven, UZ Gasthuisberg, B-3000 Leuven, Belgium.
Background:
The study aimed at evaluating the potential benefit from a combination of fractionated ionising radiation with the vascular-targeting compound combretastatin A-4 phosphate (CA-4-P).
Materials And Methods:
Syngenic rat rhabdomyosarcoma (R1), growing subcutaneously, was treated at 2 different sizes: either small (2 +/- 0.5 cm3) or large (10.94 +/- 0.6 cm3). Localised fractionated irradiation of the tumours (5 x 3 Gy) in 5 days was followed 1 day later by an intraperitoneal CA-4-P treatment (25 mglkg).
Results:
The combined treatment of only large tumours resulted in a small additional growth delay when compared with radiotherapy only.
Conclusion:
The present data indicate a size-dependent increase in tumour growth delay from combining fractionated irradiation with CA-4-P.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy